CD8A and ovarian cancer: For instance, in NY-ESO-1 ovarian cancer samples, LAG-3 and PD-1 collaborate to mark dysfunctional CD8+ T cells, both of which attenuate CD8+ T cells activation, inhibit cytokines secretion, and take part in immune escape of tumor cells [37].